Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles